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Abstract
Background: Diabetes mellitus (DM) is associated with an increased risk of ischemic heart disease and of adverse outcomes
following myocardial infarction (MI). Here we assessed the role of endoplasmic reticulum (ER) stress in ventricular
dysfunction and outcomes after MI in type 2 DM (T2DM).
Methodology and Principal Findings: In hearts of OLETF, a rat model of T2DM, at 25,30 weeks of age, GRP78 and GRP94,
markers of ER stress, were increased and sarcoplasmic reticulum calcium ATPase (SERCA)2a protein was reduced by 35%
compared with those in LETO, a non-diabetic control. SERCA2a mRNA levels were similar, but SERCA2a protein was more
ubiquitinated in OLETF than in LETO. Left ventricular (LV) end-diastolic elastance (Eed) was higher in OLETF than in LETO
(53.965.2 vs. 20.265.6 mmHg/ml), whereas LV end-systolic elastance and positive inotropic responses to b-adrenergic
stimulation were similar in OLETF and LETO. 4-Phenylbutyric acid (4-PBA), an ER stress modulator, suppressed both GRP up-
regulation and SERCA2a ubiquitination and normalized SERCA2a protein level and Eed in OLETF. Sodium tauroursodeoxy-
cholic acid, a structurally different ER stress modulator, also restored SERCA2a protein level in OLETF. Though LV dysfunction
was modest, mortality within 48 h after coronary occlusion was markedly higher in OLETF than in LETO (61.3% vs. 7.7%).
Telemetric recording showed that rapid progression of heart failure was responsible for the high mortality rate in OLETF. ER
stress modulators failed to reduce the mortality rate after MI in OLETF.
Conclusions: ER stress reduces SERCA2a protein via its augmented ubiquitination and degradation, leading to LV diastolic
dysfunction in T2DM. Even at a stage without systolic LV dysfunction, susceptibility to lethal heart failure after infarction is
markedly increased, which cannot be explained by ER stress or change in myocardial response to sympathetic nerve
activation.
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Introduction
Diabetes mellitus (DM) is associated with an increased risk of
coronary artery disease and of adverse outcomes following
myocardial infarction (MI), including death and recurrent
myocardial infarction (MI) [1]. The risk of non-ischemic heart
failure is also increased by DM [1,2]. Multiple factors, including
impaired Ca
2+ homeostasis, increased oxidative stress and
mitochondrial dysfunction, have been suggested to contribute to
DM-induced myocardial dysfunction, so-called ‘‘DM cardiomy-
opathy’’ [2]. However, severity and characteristics of ventricular
dysfunction in diabetic hearts are different depending on the type
and duration of DM and animal species [2–7]. In fact, effects of
DM on mortality rate after MI were discrepant in earlier
laboratory investigations, and the mechanisms of reduced post-
MI survival in DM are still uncertain [5,6,8,9].
In the present study, we aimed to determine the role of
endoplasmic reticulum (ER) stress in ventricular dysfunction at an
early stage of DM cardiomyopathy and outcomes after MI in type
2 DM (T2DM). We focused on ER stress in the myocardium for
three reasons. First, accumulating evidence indicates significant
roles of ER stress in the pathophysiology of DM [10,11]. Second, it
has been shown that sarcoplasmic reticulum (SR) plays a pivotal
role in Ca
2+ handling and that SR dysfunction leads to contractile
dysfunction of the heart [12]. Third, recent studies showed that
increased ER stress contributes to apoptosis of cardiomyocytes in
streptozotocin-induced DM [13] and to impairment of cardiopro-
tective signaling in rat model of T2DM [14]. DM has been shown
to reduce SR calcium ATPase (SERCA)2a expression in the heart,
which was causally related with contractile dysfunction in earlier
studies [15–20]. We used Otsuka Long-Evans-Tokushima Fatty
rats (OLETF), an established model of spontaneously developing
T2DM, at ages of 25,30 weeks in this study. Our previous studies
[14,21] have shown that OLETF at these ages have the metabolic
phenotype of hyperinsulinemic T2DM and increased levels of
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39893GRP78 and GRP94, ER stress markers, in the myocardium.
Acute responses of heart rate and blood pressure to coronary
artery occlusion in OLETF were not significantly different from
those in their non-diabetic controls, Long-Evans-Tokushima Fatty
rats (LETO) [14,21], indicating absence of severe loss of
ventricular contractile reserve in OLETF at ages of 25,30 weeks
old. In contrast, significant reduction in ventricular contractility
has been reported for OLETF at 70,80 weeks of age [18]. Results
of the present study suggest that ER stress-mediated enhancement
of SERCA2a ubiquitination is responsible for down-regulation of
SERCA2a protein expression and diastolic dysfunction of the
heart. Although ventricular contractility at rest and upon b-
adrenergic stimulation was preserved in 25,30-week-old OLETF,
mortality rate after MI was eight-fold higher than that in the non-
diabetic controls due to an ER stress-independent mechanism.
Results
Hemodynamics and Blood Glucose Level in a Conscious
State
As in our previous studies [14,21], OLETF had larger body
weight and higher blood glucose level than those of LETO,
indicating a phenotype of T2DM (Table 1). Mean blood pressure,
but not heart rate, in a conscious state was higher by
approximately 20 mmHg in OLETF than in LETO. Pretreatment
with 4-phenylbutyric acid (4-PBA), an ER stress modulator [22],
did not modify body weight or hemodynamics but reduced blood
glucose level by 36% in OLETF, whereas none of these
parameters were changed by pretreatment with cyclosporine A,
an inhibitor of calcineurin.
LV Functions and Response to b-adrenoceptor
Stimulation
Under pentobarbital anesthesia, heart rate was lower and left
ventricular (LV) end-systolic pressure was higher in OLETF than
in LETO (Table 2). Since the difference in heart rate was
undetectable under conscious state (Table 1), the anesthesia might
have unmasked alterations in heart rate regulation by the
autonomic nervous system in OLETF. LV wall thickness
determined by echocardiography was significantly larger in
OLETF than in LETO (Table 3). However, there were no
differences in LV luminal dimension and fractional shortening
measured by echocardiography between OLETF and LETO
groups.
In contrast to the reported reduction in LV end-systolic
elastance (Ees) in OLETF at ages of 70,80 weeks old [18], Ees
and other indices of systolic functions determined by pressure-
volume (P-V) loop analysis in 25,30 week-old-OLETF were not
significantly reduced compared with those in LETO. Treatment
with 4-PBA or cyclosporine A and did not modify these
parameters in OLETF (Tables 2 and 3). Other loading
condition-dependent and independent parameters of systolic
function were also similar among LETO, OLETF and OLETF
treated with 4-PBA (Figure 1 and Table 2). Although values of
time constant of LV pressure decay (tau) were similar in OLETF
Table 1. Body weight, hemodynamics and blood glucose level.
LETO OLETF OLETF OLETF
+4-PBA +cyclosporine A
(n=14) (n=17) (n=15) (n=13)
Body weight (g) 542676 4 1 613* 632610* 65769*
Blood glucose (mg/dl) 137662 7 4 614* 175611{ 258621*
Heart rate (beats/min) 345693 3 9 66 32766 33065
Mean blood pressure (mmHg) 92631 1 2 62* 11764* 11362*
Values are means6SEM.
*P,0.05 vs. LETO.
{P,0.05 vs. OLETF.
4-PBA =4-phenylbutyric acid.
doi:10.1371/journal.pone.0039893.t001
Table 2. Summary data from pressure-volume relationships.
LETO OLETF OLETF+4-PBA
(n=5) (n=6) (n=6)
Body weight (g) 533617 605626* 624614*
Heart weight (g) 1.5360.05 1.8360.11* 1.7460.02
Heart weight/Body weight
(%)
0.2960.01 0.3060.01 0.2860.01
HR (beats/min) 391683 4 1 616* 32769*
LVESP (mmHg) 100.561.6 133.263.2* 136.269.1*
LVEDP (mmHg) 10.463.0 5.561.8 4.662.3
LVEDV (ml) 0.1460.012 0.1760.013 0.1860.019
LVESV (ml) 0.0660.005 0.0960.012 0.0760.013
SV (ml) 0.0860.009 0.0960.017 0.1160.008*
LVEF (%) 56.363.4 50.864.2 62.463.8
CO (ml/min) 30.663.1 29.062.4 37.363.3
LV dP/dtmax (mmHg/s) 66656805 74696356 86606555
LV dP/dtmin (mmHg/s) 268246545 286336561* 294286276*
tau (ms) 10.261.1 9.761.7 10.361.2
Ees (mmHg/ml) 33926567 33976418 27486356
Eed (mmHg/ml) 20.265.6 53.965.2* 24.266.0
Vp (ml) 0.1960.02 0.2060.01 0.2060.01
Values are means6SEM. *P,0.05 vs. LETO. HR= heart rate; LVESP= left
ventricular end-systolic pressure; LVEDP= left ventricular end-diastolic
pressure; LVEDV= left ventricular end-diastolic volume; LVESV= left ventricular
end-systolic volume; LVEF= left ventricular ejection fraction; CO= cardiac
output; LV dP/dtmax and dP/dtmin= left ventricular maximal slope of the
systolic pressure increment and the diastolic pressure decrement, respectively;
tau= time constant of left ventricular pressure decay; Ees= end-systolic
elastance of left ventricle; Eed= end-diastolic elastance of left ventricle; Vp=
parallel conductance volume.
doi:10.1371/journal.pone.0039893.t002
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pressure-volume relationship, was significantly larger in OLETF
than in LETO (53.965.2 vs. 20.265.6 mmHg/ml). Treatment
with 4-PBA normalized Eed in OLETF (Eed=24.266.0 mmHg/
ml). LV dP/dtmin was paradoxically larger in OLTEF than in
LETO, but the difference is attributable to different LV loading
conditions indicated by differences in heart rate and LV end-
systolic pressure between the two groups (Table 2).
Infusion of dobutamine (5,10 mg/kg/min) increased heart
rate, LVdP/dtmax and Ees in LETO. These positive inotropic
responses to dobutamine were similarly induced in OLETF with
or without 4-PBA pretreatment (Figure 2). Responses of tau and
Eed to dobutamine were also similar in the three study groups.
Expression of ER Stress Markers and Sarcoplasmic
Proteins: Immunoblot and qRT-PCR Data
Consistent with our previous reports, myocardial levels of
GRP78 and GRP94, markers of ER stress, were significantly
higher in OLETF than in LETO (Figure 3). Like sodium
tauroursodeoxycholic acid (TUDCA), a chemical chaperone, in
our previous study [14], 4-PBA normalized levels of glucose-
regulated protein (GRP)78 and GRP94 in OLETF in the present
study. Levels of phospho-eIF2a and spliced X-box binding protein
(XBP)-1 were similar in OLETF and LETO. Other ER stress-
related proteins, including IRE1a, PERK and ATF6, could not be
detected in the rat myocardium by immunoblotting in the present
experiments (data not shown), though their mRNAs levels detected
by DNA microarray analysis were similar in LETO and OLETF
in our preliminary experiments.
Protein level of SERCA2a was significantly reduced by 35% in
OLETF, and this reduction was restored by treatment with 4-PBA
(Figure 4AB). Phospholamban level and its phosphorylation were
not statistically significant (Figure 4AC). Protein levels of
ryanodine receptor 2 were also similar in the study groups
(Figure 4D). A post-hoc experiment using TUDCA confirmed that
the reduction of SERCA2a protein in OLETF was restored by
suppression of ER stress (Figure 4E).
As for the mechanism by which SERCA2a protein level is
reduced in OLETF, we first determined SERCA2a mRNA levels
in OLETF and LETO. However, there was no significant
difference between SERCA2a mRNA levels in LETO and
OLETF with and without 4-PBA (Figure 5A). Second, we
examined whether activity of the ubiquitination-proteasome
pathway is enhanced in OLETF. As shown in Figure 5B and
5C, ubiquitination of SERCA2a protein was significantly
increased by 85% in OLETF compared with that in LETO.
Interestingly, this enhanced ubiquitination of SERCA2a protein in
OLETF was attenuated by 4-PBA.
To examine the possibility that O-glycosamine-N-acetylation
(O-GlcNAcylation) of SERCA2a is a mechanism of its hyper-
ubiquitination in OLETF, we determined level of N-acetylgluco-
samine (GlcNAc) in immunoprecipitated SERCA2a by using anti-
GlcNAc antibody (RL-2). However, there was no significant
difference between GlcNAc levels in LETO, OLETF and 4-PBA-
treated OLETF (data not shown).
Ventricular Function and Mortality After MI
Echocardiography showed that thickening of the LV anterior
wall was severely impaired 1 h after coronary ligation in all
animals. There were no significant differences in LV dimension,
fractional shortening and size of akinetic areas between the
treatment groups, indicating that there was no inter-group
difference in infarct sizes (Table 4). The survival rate within
48 h after MI was significantly lower in control OLETF than in
LETO (Figure 6). Telemetric monitoring of ECG and blood
pressure after MI in a group of OLETF (n=5) showed that
progressive hypotension preceded bradycardia and cardiac
arrest, and ventricular tachycardia or fibrillation preceding
hypotension was not observed in any cases. The findings
indicate that progression of heart failure, but not ventricular
arrhythmias, was responsible for the increased post-MI mortal-
ity. The survival rate in OLETF was not significantly improved
by either 4-PBA or cyclosporine A. To confirm the lack of a
significant effect of ER stress suppression, we additionally
examined the effect of TUDCA in a post-hoc series of
experiments. TUDCA also failed to improve survival rates after
MI (Figure 6). In additional series of post-hoc series of MI
experiments, we doubled the dose of 4-PBA in OLETF (n=7),
but the mortality rate within 48 h after MI was not reduced
(Figure 6). On the other hand, only one of five LETO
pretreated with 4-PBA died within 48 h after MI, indicating
that 4-PBA alone did not change the post-MI mortality rate.
In agreement with echocardiographic data, histological analysis
confirmed that there was no significant difference between the five
study groups in mean sizes of infarct, ranging from 38.2 to 41.4%
of the LV. The numbers of Factor VIII-positive vessels in the
infarct areas and border-zone areas were similar in the groups
(data not shown).
Discussion
Reduction of SERCA2a protein by diabetes has been known
for some time, but its mechanism remains unclear. The mRNA
level of SERCA2a has been reported to be reduced in some,
but not all, models of diabetes [15–20]. A plausible explanation
for the different findings in previous studies is the possibility that
impaired transcription of the SECRA2a gene is a late event in
the natural history of DM and is preceded by reduction in
SERCA2a protein by non-transcriptional mechanisms. As for
the mechanism of DM-induced suppression of SERCA2a
transcription, O-GlcNAcylation of nuclear protein has been
Table 3. Echocardiographic data at baseline.
LETO OLETF OLETF OLETF
+4-PBA
+cyclosporine
A
(n=13) (n=25) (n=13) (n=14)
LVEF (%) 80.960.7 79.960.7 80.660.6 80.560.6
%FS 44.760.7 43.960.7 44.560.6 44.460.6
IVST (mm) 1.5660.07 1.8660.05* 1.8060.06* 1.8060.06*
PWT (mm) 2.0560.08 2.2260.05 2.1260.04 2.3260.06*
LVEDD (mm) 7.7360.25 8.0160.12 8.1160.10 8.1360.15
LVESD (mm) 4.3160.17 4.4860.08 4.4960.07 4.4660.13
LVEDV (ml) 1.0560.08 1.1460.04 1.1760.04 1.1260.07
LVESV (ml) 0.2160.02 0.2360.01 0.2360.01 0.2360.19
Values are means6SEM. *P,0.05 vs. LETO. 4-PBA=4-phenylbutyric acid; LVEF=
left ventricular ejection fraction; %FS= fractional shortening; IVST=
interventricular septal thickness; PWT= posterior wall thickness; LVEDD= left
ventricular end-diastolic dimension; LVESD= left ventricular end-systolic
dimension; LVEDV= left ventricular end-diastolic volume; LVESV= left
ventricular end-systolic volume.
doi:10.1371/journal.pone.0039893.t003
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showed that hyperglycemia reduced both mRNA level and
promoter activity of SERCA2a in isolated cardiomyocytes and
that the effect of hyperglycemia on SERCA2a was attenuated
by overexpression of O-GlcNAcase and mimicked by overex-
pression of O-GlcNAc-transferase. On the other hand, how
SERCA2a protein level in diabetic hearts is reduced in the
absence of change in SERCA2a mRNA level [17] was unclear.
In the present study, treatment with both 4-PBA and TUDCA
restored SERCA2a protein level in OLETF, and comparable
results were recently reported for obese ob/ob mice by Ceylan-
lsik et al. [24] using TUDCA. Furthermore, the present study
showed for the first time that SERCA2a in OLETF is
hyperubiquitinated and that the hyperubiquitination was signif-
icantly attenuated by 4-PBA (Figure 5). Taken together, the
findings suggest that ER stress-mediated hyperubiquitination
and subsequent degradation of SERCA2a is a mechanism of
DM-induced down-regulation of SERCA2a in an early phase of
DM (i.e., a phase preceding the down-regulation of SERCA2a
mRNA level).
Mechanism by which ER stress induces hyperubiquitination of
SERCA2a in OLETF remains unclear. We hypothesized that O-
GlcNAcylation of SERCA2a primes hyperubiquitination of this
protein in diabetes based on a recent report that hyperubiquitina-
tion of atheroprotective protein A20 in diabetic smooth muscle
cells is mediated by O-GlcNAcylation [25]. However, this
hypothesis was argued against by the results that levels of O-
GlcNAcylation of SERCA2a were similar in LETO, OLETF and
4-PBA-treated OLETF. As another type of post-translational
modification, formation of advanced glycation end-product (AGE)
on SERCA has been reported in streptozotocin-induced diabetic
rats [17]. However, relationship between AGE and ubiquitina-
tion/proteasome pathway is currently unknown and warrants
further investigation.
As observed in patients with an early stage of DM cardiomy-
opathy [26,27], OLETF at ages of 25,30 weeks showed
significant impairment of diastolic LV function without systolic
Figure 1. LV functions determined by pressure-volume relationships. Representative examples of pressure-volume relationships in LETO (A)
and OLETF (B) and summary data of LVEDP (C), tau (D), LV Ees (E), and LV Eed (F) are shown. *p,0.05 vs. LETO, {p,0.05 vs. OLETF. n=5,6. LVEDP=
left ventricular end-diastolic pressure; tau= time constant of left ventricular pressure decay; Ees= end-systolic elastance; Eed= end-diastolic
elastance; 4-PBA=4-phenylbutyric acid.
doi:10.1371/journal.pone.0039893.g001
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dysfunction was indicated by results showing that 4-PBA
normalized Eed in OLETF. In ventricular dysfunction induced
by diabetes, multiple mechanisms, including down-regulation of
SERCA2a, reduced phosphorylation of phospholamban and
leakage of Ca
2+ from SR, and increased collagen deposition in
the extracellular matrix [28–30], have been proposed. In the
present study, 4-PBA restored SERCA2a protein level, while levels
of phospholamban phosphorylation at Thr17 and Ser16 and
ryanodine receptor protein were not modified by 4-PBA. There
was no discernible difference in the extent of interstitial fibrosis
between OLETF and LETO (data not shown). Thus, normaliza-
tion of Eed by 4-PBA is likely to be due to normalized SERCA2a
expression and Ca
2+ uptake into the SR during diastole, though
the possibility of involvement of other 4-PBA targets cannot be
excluded.
Down-regulation of SERCA2a occurs in not only diabetic
hearts but also other types of heart failure [12]. Gene therapy
using an adenovirus or adenovirus-associated virus has been
designed to restore SERCA2a protein level in failing hearts for
improving ventricular function and/or ventricular arrhythmias.
In fact, several groups have reported that such SERCA2a gene
therapy significantly attenuated systolic dysfunction in diabetic
hearts [18,31–33]. Although the ventricular dysfunction was very
Figure 2. Responses of LV functions to b-adrenoceptor stimulation. Responses of heart rate (A), tau (B), LVESP (C), LVEDP (D), LVdP/dtmax (E),
LVdP/dtmin (F), Ees (G) and Eed (H) to intravenous infusion of dobutamine are shown. *p,0.05 vs. Baseline (Base), {p,0.05 vs. LETO. n=5,6. tau=
time constant of left ventricular pressure decay; LVESP= left ventricular end-systolic pressure; LVEDP= left ventricular end-diastolic pressure; LVdP/
dtmax= left ventricular maximal slope of the systolic pressure increment; LVdP/dtmin= left ventricular maximal slope of the diastolic pressure
decrement; Ees= end-systolic elastance; Eed= end-diastolic elastance; 4-PBA=4-phenylbutyric acid.
doi:10.1371/journal.pone.0039893.g002
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successfully restored SERCA2a level and diastolic function.
Recently, systolic ventricular dysfunction in obese diabetic mice
(obese ob/ob mice) was shown to be improved by TUDCA,
indicating that the role of ER stress is not limited to diastolic
dysfunction [24]. Furthermore, increase in ER stress has been
demonstrated in heart failure induced by pressure overload and
by coronary embolization [34–36], indicating a possible role of
ER stress in the pathogenesis of heart failure in general.
Nevertheless, chemical chaperones are clinically more feasible
than viral vectors [37], and their effects on failing hearts warrant
future investigations.
To our surprise, the mortality rate after MI was markedly
increased in OLETF compared with that in LETO (Figure 6A),
though there was only a modest difference in Eed and no
difference in Ees or LV ejection fractions between OLETF and
LETO. The increased mortality rate in OLETF is consistent with
increased mortality rates in previous studies in which infarct size
was larger than 20% of the left ventricle in different animal models
of diabetes (i.e., Goto-Kakizaki rats, high fat diet-induced DM,
streptozotocin-induced DM) [5,6,9]. However, the mechanism by
which DM increases mortality during the acute phase of MI has
not been explored. Telemetric analysis in the present study showed
that progression of heart failure, not ventricular arrhythmia, was
responsible for the higher mortality. As a possible reason for the
high post-MI mortality in OLETF, we first postulated the
possibility that compensatory increase in contraction of the non-
ischemic region after MI is attenuated due to reduced Ca
2+ store
Figure 3. ER stress-related proteins in OLETF and LETO. Representative blots (upper panel) and summary of data (lower panel) from
immnoblotting of GRP78 (A), GRP94 (B), phospho-eIF2a (C), and spliced XBP1 (D) are shown. *p,0.05 vs. LETO. {p,0.05 vs. OLETF. n=6,8. GRP78=
glucose-regulated protein 78; GRP94= glucose-regulated protein 94; eIF2a= eukaryotic initiation factor 2a; XBP-1= X-box binding protein-1; 4-
PBA=4-phenylbutyric acid.
doi:10.1371/journal.pone.0039893.g003
ER Stress in Diabetic Heart
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39893in the SR and/or autonomic dysfunction associated with DM.
However, this possibility was not supported by results showing that
responses of Ees, Eed and dP/dts to dobutamine infusion were
similar in OLETF and LETO (Figure 1).
We then postulated that defective LV diastolic function or loss
of cytoprotective signaling underlies the high post-MI mortality in
OLETF. However, this hypothesis was argued against by results
showing that 4-PBA, TUDCA or cyclosporine A did not improve
survival of OLETF after MI, though doses of the chemical
chaperones and cyclosporine A were sufficient for normalizing LV
Eed in this study (Figure 1) and for repairing defective
cardioprotective signaling, respectively, in OLETF [21]. One of
remaining possible explanations for the high mortality in OLETF
is increased volume retention by augmented activation of the
renin-angiotensin system (RAS) after MI in OLETF. To critically
test the hypothesis, a future study will be necessary for examining
differences in time courses of the RAS activation, fluid balance
and hemodynamic parameters after MI between OLETF and
LETO.
In conclusion, ER stress reduces SERCA2a protein via its
augmented ubiquitination and degradation, leading to LV
diastolic dysfunction in T2DM. Even at a stage of modest diastolic
LV dysfunction, susceptibility of diabetic hearts to lethal heart
failure after MI is substantially increased, and the susceptibility
cannot be explained by reduced SERCA2a expression, up-
regulated calcineurin activity or impaired myocardial response to
sympathetic nerve activation.
Materials and Methods
The present study was conducted in strict accordance with The
Guide for the Care and Use of Laboratory Animals published by
Figure 4. Sarcoplasmic proteins in OLETF and LETO. Representative blots (A) and summary of data from immnoblotting of SERCA2a (B), total
PLN, and phospho-PLN at Ser16 and Thr17 (C), and RyR2 (D) are shown. n=8,15. Representative blots (upper panel) and summary of data (lower
panel) from immnoblotting of SERCA2a (E) in a post-hoc experiment (n=5) is also shown. *p,0.05 vs. LETO. { p,0.05 vs. OLETF. SERCA2a=
sarcoplasmic reticulum calcium ATPase 2a; PLN= phospholamban; RyR= ryanodine receptor; 4-PBA=4-phenylbutyric acid; TUDCA= sodium
tauroursodeoxycholic acid.
doi:10.1371/journal.pone.0039893.g004
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revised 1996) and was approved by the Animal Use Committee of
Sapporo Medical University (#08-148_10-083).
Animals
LETO and OLETF at ages of 25,30 weeks were kindly
provided by the Tokushima Research Institute of Otsuka
Pharmaceutical, Tokushima, Japan. LETO and OLETF were
pretreated with saline or 4-phenylbutyric acid (4-PBA, 40 mg/kg/
day, i.p.), an ER stress modulator, for 1 week before the
experiments. 4-PBA acts as a chemical chaperone, assisting with
protein folding and thus reducing ER stress [22]. In MI
experiments, LETO received saline and OLETF received saline,
4-PBA or cyclosporine A (20 mg/kg/day, i.p.) for 1 week before
induction of MI. The same dose of cyclosporine A has been shown
Figure 5. Alterations in mRNA expression and ubiquitination of SERCA2a in OLETF. Summary data of SERCA2a mRNA (A), representative
blot (B) and summary data (C) of ubiquitination of SERCA2a protein are shown. *p,0.05 vs. LETO, {p,0.05 vs. OLETF. n=5. SERCA2a= sarcoplasmic
reticulum calcium ATPase 2a; 4-PBA=4-phenylbutyric acid.
doi:10.1371/journal.pone.0039893.g005
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by up-regulated calcineurin in OLETF [21]. To confirm the
results in 4-PBA-treated OLETF, a study group was added post-hoc
by use of a structurally different chemical chaperone, sodium
tauroursodeoxycholic acid (TUDCA) [14,38]. TUDCA at a dose
of 100 mg/kg/day (i.p.) was administered to an additional group
of OLETF for 1 week before the experiment. As a post-hoc series of
MI experiments, we examined the effect of 4-PBA (40 mg/kg/day,
i.p. for 7 days) in LETO and a higher dose of 4-PBA (80 mg/kg/
day, i.p. for 7 days) in OLETF.
Measurements of Baseline Heart Rate and Blood Pressure
Systemic blood pressure and pulse rate were measured in a
conscious state using a tail-cuff system (BP-98A, Softran, Tokyo,
Japan). Rats were placed in a restrainer for 15 min, and then a cuff
was attached to their tail and blood pressure and heart rate were
measured.
Echocardiography
Each rat was lightly sedated with 3–4% isoflurane, and then the
chest was shaved and the rat was placed in the supine position.
Echocardiography was performed at baseline and 1 h after
induction of MI using a 11.5 MHz transducer connected to a
Vivid-i Cardiovascular Ultrasound System (GE Medical, Milwau-
kee, USA). M-mode and 2-dimensional images at the papillary
muscle level were acquired with a frame rate of 88.9/sec.
Interventricular septal thickness (IVST), posterior wall thickness
(PWT), LV end-diastolic dimension (LVEDD) and LV end-systolic
dimension (LVESD) were measured. LV fractional shortening (FS)
was calculated by the following formula: FS (%) = (LVEDD-
LVESD)/LVEDD.
P-V Loop Analyses
Rats were anesthetized with pentobarbital sodium (40 mg/kg,
i.p.) and the adequacy of anesthesia was confirmed by disappear-
ance of eyelid reflex, corneal reflex, loss of muscular tone, and no
response to surgical manipulation. The level of anesthesia was
continuously monitored during the experiment and an additional
dose of pentobarbital (10 mg/kg, i.v.) was administered when
necessary. After confirmation of the adequacy of anesthesia, rats
were intubated and ventilated with a rodent respirator (model 683,
Harvard Apparatus, South Natick, MA). The LV P-V relationship
was determined by the method previously reported [39,40]. A 3-F
catheter-tip micromanometer (Miller Instruments, Houston, TX)
was inserted into the LV cavity through the right carotid artery.
An incision over the xyphoid was made and the diaphragm was
cut to expose the apex of the heart, and then a conductance
catheter with a 2-mm inter-electrode distance (Unique Medical,
Tokyo, Japan) was inserted into the LV cavity through the apex.
The distal driving electrode and proximal electrode were
Table 4. Echocardiographic data at 1 hr after coronary
ligation.
LETO OLETF OLETF OLETF
+4-PBA
+cyclosporine
A
(n=12) (n=22) (n=13) (n=13)
LVEF (%) 36.362.2 39.361.2 41.361.6 40.960.9
%FS 15.261.1 16.660.6 17.660.8 17.460.5
IVST (mm) 1.5260.09 1.7460.05 1.8260.06* 1.7160.08
PWT (mm) 1.7360.09 1.9660.04 2.0660.05* 1.9760.11
LVEDD (mm) 7.7860.41 8.1260.16 7.4860.29 7.8160.25
LVESD (mm) 6.6160.34 6.7860.16 6.2760.27 6.4560.21
LVEDV (ml) 1.1160.17 1.1960.06 1.0160.09 1.0760.09
LVESV (ml) 0.7060.09 0.7260.05 0.6160.07 0.6360.06
akinetic area (%) 37633 8 624 0 633 9 61
Values are means6SEM. *P,0.05 vs. LETO. Abbreviations: See Table 2.
Echocardiographic data was not acquired from 1 rat in LETO, 3 in OLETF and 1
in OLETF+cyclosporine A because of the poor quality of echocardiographic
images.
doi:10.1371/journal.pone.0039893.t004
Figure 6. Survival after myocardial infarction. Kaplan-Meier survival analysis of rats with acute myocardial infarction. *p,0.05 vs. LETO. 4-PBA
= pretreatment with 4-PBA at dose of 40 mg/kg/day; 4-PBA80= pretreatment with 4-PBA at a dose of 80 mg/kg/day; Cyclosporine A =
pretreatment with cyclosporine A at dose of 20 mg/kg/day; TUDCA= pretreatment with sodium tauroursodeoxycholic acid (100 mg/kg/day). All
agents were administered intraperitoneally for 7 days before infarct experiments. Experiments using TUDCA and a higher dose of 4-PBA (i.e., 4-PBA80
group) were additionally performed as post-hoc experiments.
doi:10.1371/journal.pone.0039893.g006
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respectively. To obtain LV P-V loops, we used a string-occluder to
gradually occlude the inferior vena cava until LV end-diastolic
volume (LVEDV) slightly decreased. The respirator was turned off
during data acquisition to avoid respiratory-mediated hemody-
namic fluctuation. For measurement of a parallel conductance
volume, 0.02 mL of 5% NaCl solution was injected into the
pulmonary artery, which transiently changed LV blood conduc-
tivity. The LV conductance volume was calculated by subtraction
of the parallel conductance volume from the actual measured
volume. Finally, blood sample conductivity was measured using a
small cuvette. Integral 3 (Unique Medical) was used to store data
from the conductance catheter and tip-manometer and to
calculate the systolic and diastolic functional parameters, including
Ees. To assess the possibility that myocardial response to b-
adrenoceptor activation is modified in OLETF, we determined
hemodynamic responses to dobutamine. Rats received infusion of
dobutamine (5 and 10 mg/kg/min) for 4 min, during which time
heart rate, arterial blood pressures, LV pressures, and LVdP/dt
were continuously recorded as described above.
Immunoblotting Study
Rats were anesthetized and ventilated as in LV P-V loop
analysis experiments. Under anesthesia, hearts of the rats were
excised and perfused with non-circulating Krebs-Henseleit buffer
(NaCl 118.5, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, NaHCO3 24.8,
CaCl2 2.5 and glucose 10 mmol/L) at a pressure of 75 mmHg as
previously reported [41]. The buffer was continuously gassed with
95% O2/5% CO2, and the temperature of the perfusate was
maintained at 38uC. Myocardial tissues (0.8,1.0 g) were sampled
from the left ventricle and immediately frozen in liquid nitrogen
and stored at 280uC until use for biochemical analysis. Total
homogenates or sarcoplasmic reticulum fractions were prepared
for immunoblotting. The sarcoplasmic reticulum preparation was
isolated by the method previously described [42]. Tissue samples
were homogenized in ice-cold buffer containing
10 mM NaHCO3, 5 mM NaN3, and 15 mM Tris-HCl
(pH 6.8). The homogenate was centrifuged at 10,000 g for
20 min at 4uC to obtain the supernatant. The supernatant was
further centrifuged at 40,000 g for 45 min at 4uC. The pellet was
suspended in a buffer containing 0.6 M KCl and 20 mM Tris-
HCl (pH 6.8) and then recentrifuged at 40,000 g for 45 min at
4uC. The final pellet was suspended in a mixture of 250 mM
sucrose and 10 mM histidine (pH 7.0) and used for immunoblot-
ting. All solutions contained 0.1% phenylmethylsulfonyl fluoride.
Protein concentration was determined using a Bio-Rad Protein
Assay Kit (Bio-Rad, Hercules, CA). Equal amounts of protein
were analyzed by immunoblot assays using antibodies that
recognize the following proteins: SERCA2a (Abcam, Cambridge,
MA), Ser16-phosphorylated phospholamban (PLN) (Upstate,
Temecula, CA), Thr17-phosphorylated PLN (Santa Cruz Bio-
technology, Santa Cruz, CA), total PLN (Thermo Scientific,
Rockford, IL), ryanodine receptor 2 (CHEMICON International,
Temecula, CA), GRP78 (Cell Signaling Technology, Beverly,
MA), GRP94 (Zymed, Carlsbad, CA), phosphor-eIF2a (Invitro-
gen, Camarillo, CA), total eIF2a (Cell Signaling Technology),
spliced XBP-1 (Santa Cruz Biotechnology), phosphor-PERK (Cell
Signaling Technology), total PERK (Rockland, Gilbertsville, PA),
phosphor-IRE1a (Novus Biologicals, Littleton, CO), total IRE1a
(Cell Signaling Technology), ATF6 (Imgenex, San Diego, CA) and
vinculin (Sigma Aldrich, St. Louis, MO). PVDF membranes were
first used for blotting of phosphorylated proteins. The blot was
then stripped by a Re-Blot Western Recycling Kit (CHEMICON
International, Temecula, CA) for re-blotting of total proteins and
loading controls. Equal loading of protein onto each lane in the gel
was confirmed later from comparable levels of vinculin protein
and/or comparable densitometric levels of protein bands in the
gels stained with Coomasie Brilliant Blue. Immunoblotted proteins
were visualized by using an Immobilon Western detection kit
(Millipore, Billerica, MA) and quantified by a lumino-image
analyzer, LAS-2000mini (Fujifilm, Tokyo, Japan).
Immunoprecipitation Study
An equal amount of protein (500 mg) from the sarcoplasmic
reticulum fraction used in immunoblotting was solubilized in a
CelLytic
TM MT Mammalian Tissue Lysis/Extraction Reagent
(Sigma Aldrich) including protease inhibitor cocktail (Nakalai
Tesque, Kyoto, Japan) and a proteasome inhibitor, MG132,
(10 mM) for 60 min at 4uC. The lysates were incubated for 30 min
with protein A/G PLUS-agarose (Santa Cruz) to remove
endogenous IgG. Then either 2 ml of the anti-SERCA2a antibody
or normal mouse IgG was added to precleared lysates and
incubated overnight at 4uC. Protein A/G PLUS-agarose slurry
was added and rotary mixed for 60 min at 4uC. The slurry was
centrifuged at 4uC for 5 min and washed 4 times by using PBS
with protease inhibitor cocktail and MG132. Finally, the
immunoprecipitated proteins were subjected to SDS-PAGE and
transferred to PVDF membranes. Membranes were first used for
blotting of the rabbit polyclonal ubiquitin antibody (1:250, Santa
Cruz, sc-9133) or anti-N-Acetylglucosamine (RL-2) (AbCam,
Cambridge, MA) and then stripped and reblotted with the mouse
monoclonal SERCA2a antibody (1:2000).
Quantitative Reverse Transcription Polymerase Chain
Reaction (qRT-PCR)
Total RNA was isolated from rat LV tissues by using the
RNeasy Fibrous Tissue Mini Kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. First-strand cDNA
was synthesized using SuperScript III (Invitrogen, Carlsbad, CA).
DNA amplification was performed in StepOneTM (Applied
Biosystems, Foster City, CA) using the Power SYBR Green
Master Mix (Applied Biosystems). The following primer pairs were
used: 59-GAAGCCATCAGCCAAGTCTC-39 and 59-
CAGGGCCAATTAGAGAGCAG-39 for Serca2a, 59-TCAC-
CACCATGGAGAAGGC-39 and 59-GCTAAG-
CAGTTGGTGGTGCA-39 for GAPDH. All assays were per-
formed in duplicate. Relative abundance of SERCA2a mRNA
was examined by the standard curve method using serial cDNA
dilution and was normalized by GAPDH as an internal control.
GAPDH mRNA levels were similar in LETO, OLETF,
4PBA+LETO, and 4PBA+OLETF groups (data not shown).
MI Study
OLETF and LETO were pretreated with saline, 4-PBA (40 mg/
kg/day, i.p.), or cyclosporin A (20 mg/kg/day, i.p.) for 1 week
before the experiments. Rats were anesthetized and ventilated as in
LV P-V loop analysis experiments. After left thoracotomy, a
coronary snare was placed around a marginal branch of the left
coronary artery by using a 5–0 silkthread, and the coronary branch
was then permanently ligated to induce myocardial infarction. The
surgical wounds were repaired and the rats were returned to their
cages for recovery. Ventricular dimensions and functions were
assessed by echocardiography before and 1 h after coronary
ligation. Survival of rats was checked at 6 h, 24 h and 48 h after
myocardial infarction. To investigate the cause of death after
infarction, a radio-telemetry device (Data Sciences International
PhysioTel)wasimplantedinagroupofOLETF(n=5)aspreviously
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which has a pressure sensor at its tip, was inserted into the
descending aorta for continuous non-tethered recording of pulsatile
arterialbloodpressure.Electricalleadsfromatelemetrydevicewere
placed in a modified lead II configuration by placing a negative
electrode to the right of the manubrium and a positive electrode at
the anterior axillary line along the 5
th intercostal space. Telemetry
system implantation was performed one week prior to induction of
myocardial infarction.
Statistics
Data are expressed as means6SEM. The survival rates after MI
were compared using Kaplan-Meier curves and log-rank statistics.
Differences between treatment groups were tested by one-way
ANOVA or two-way repeated-measures ANOVA and the
Student-Newman-Keuls post hoc test for multiple comparisons.
The difference was considered significant if the p value was ,0.05.
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